Aleck Hercbergs

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4250124/publications.pdf

Version: 2024-02-01

37 papers	869 citations	430874 18 h-index	477307 29 g-index
37 all docs	37 docs citations	37 times ranked	787 citing authors

#	Article	IF	Citations
1	Possible Contributions of Nongenomic Actions of Thyroid Hormones to the Vasculopathic Complex of COVID-19 Infection. Endocrine Research, 2022, 47, 39-44.	1.2	0
2	Role of Integrin Î±vÎ²3 in Doxycycline-Induced Anti-Proliferation in Breast Cancer Cells. Frontiers in Cell and Developmental Biology, 2022, 10, 829788.	3.7	6
3	Opposing effects of thyroid hormones on cancer risk: a population-based study. European Journal of Endocrinology, 2021, 184, 477-486.	3.7	9
4	Î±vÎ²3 Integrin Expression and Mitogenic Effects by Thyroid Hormones in Chronic Lymphocytic Leukemia. Journal of Clinical Medicine, 2021, 10, 1766.	2.4	4
5	Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors. Journal of the Endocrine Society, 2021, 5, bvab100.	0.2	9
6	Actions of Thyroid Hormones on Thyroid Cancers. Frontiers in Endocrinology, 2021, 12, 691736.	3.5	6
7	Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality. Endocrine-Related Cancer, 2021, 28, 705-713.	3.1	8
8	Coronaviruses and Integrin Î±vÎ²3: Does Thyroid Hormone Modify the Relationship?. Endocrine Research, 2020, 45, 210-215.	1.2	32
9	Actions of L-thyroxine (T4) and Tetraiodothyroacetic Acid (Tetrac) on Gene Expression in Thyroid Cancer Cells. Genes, 2020, 11, 755.	2.4	9
10	Clinical Implications and Impact of Discovery of the Thyroid Hormone Receptor on Integrin Î±vÎ²3â€“A Review. Frontiers in Endocrinology, 2019, 10, 565.	3.5	15
11	Action of Reverse T3 on Cancer Cells. Endocrine Research, 2019, 44, 148-152.	1.2	20
12	Thyroid Hormone in the Clinic and Breast Cancer. Hormones and Cancer, 2018, 9, 139-143.	4.9	38
13	Activation of tumor cell integrin Î±vÎ²3 by radiation and reversal of activation by chemically modified tetraiodothyroacetic acid (tetrac). Endocrine Research, 2018, 43, 215-219.	1.2	14
14	Nonthyroidal Illness Syndrome and Thyroid Hormone Actions at Integrin Î±vÎ²3. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1291-1295.	3.6	23
15	The Interplay Between Epithelial-Mesenchymal Transition (EMT) and the Thyroid Hormones-Î±vÎ²3 Axis in Ovarian Cancer. Hormones and Cancer, 2018, 9, 22-32.	4.9	29
16	Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells. Endocrine-Related Cancer, 2018, 25, 533-545.	3.1	46
17	Molecular insights into the transcriptional regulatory role of thyroid hormones in ovarian cancer. Molecular Carcinogenesis, 2018, 57, 97-105.	2.7	7
18	Plasma 3,3â€™,5-Triiodo-L-thyronine [T3] level mirrors changes in tumor markers in two cases of metastatic cancer of the breast and pancreas treated with exogenous L-T3. Cancer Biomarkers, 2018, 21, 433-438.	1.7	11

#	Article	IF	Citations
19	Bioactivity of Thyroid Hormone Analogs at Cancer Cells. Frontiers in Endocrinology, 2018, 9, 739.	3.5	30
20	Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers. Hormones and Cancer, 2018, 9, 349-360.	4.9	22
21	Contributions of Thyroid Hormone to Cancer Metastasis. Biomedicines, 2018, 6, 89.	3.2	39
22	Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model. Frontiers in Endocrinology, 2018, 9, 775.	3.5	9
23	Radioresistance of cancer cells, integrin Î±vÎ²3 and thyroid hormone. Oncotarget, 2018, 9, 37069-37075.	1.8	21
24	Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer. Scientific Reports, 2017, 7, 16475.	3.3	27
25	Possible contributions of thyroid hormone replacement to specific behaviors of cancer. Biomedicine and Pharmacotherapy, 2016, 84, 655-659.	5.6	5
26	Medically Induced Euthyroid Hypothyroxinemia May Extend Survival in Compassionate Need Cancer Patients: An Observational Study. Oncologist, 2015, 20, 72-76.	3.7	75
27	Low thyroid hormone levels improve survival in murine model for ocular melanoma. Oncotarget, 2015, 6, 11038-11046.	1.8	34
28	Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis. OncoTargets and Therapy, 2014, 7, 1619.	2.0	40
29	Modulation of angiogenesis by thyroid hormone and hormone analogues: implications for cancer management. Angiogenesis, 2014, 17, 463-469.	7.2	67
30	Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin ÃŽÂ±vÃŽÂ²3 by Thyroid Hormone and Nanoparticulate Tetrac. Frontiers in Endocrinology, 2014, 5, 240.	3.5	91
31	Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via Î±vÎ²3 integrin in myeloma cells. Oncotarget, 2014, 5, 6312-6322.	1.8	61
32	Molecular Mechanisms of Actions of Formulations of the Thyroid Hormone Analogue, Tetrac, on the Inflammatory Response. Endocrine Research, 2013, 38, 112-118.	1.2	23
33	Thyroid Hormones Antagonize and Tetrac, a Deaminated T4 Analog, Sensitizes Bortezomib Action in Multiple Myeloma Cells. Blood, 2011, 118, 2867-2867.	1.4	0
34	Blocking Thyroid Hormones Induced MAPK Activation -Novel Target for Therapy In Myeloma. Blood, 2010, 116, 2964-2964.	1.4	0
35	Radiosensitization of GL261 glioma cells by tetraiodothyroacetic acid (tetrac). Cell Cycle, 2009, 8, 2586-2591.	2.6	27
36	Novel Association Between Thyroid Hormones and Multiple Myeloma Cell Proliferation: a MAPK Dependent Activity.. Blood, 2009, 114, 2836-2836.	1.4	1

#	Article	IF	Citations
37	Cell-surface receptor for thyroid hormone and tumor cell proliferation. Expert Review of Endocrinology and Metabolism, 2006, 1, 753-761.	2.4	11